Latest Investment Summit News

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

Neurotech International has opened its first Phase 3 clinical site for NTI164 targeting Autism Spectrum Disorder, reported positive 90-day toxicology results, and launched a new Rett syndrome research collaboration.

Infini Resources has received drill permits to begin its inaugural diamond drilling program targeting high-grade uranium at Reynolds and Reitenbach Lake projects in northern Saskatchewan. The campaign aims to test a large, underexplored system on the eastern Athabasca Basin margin, with drilling set to start in late April 2026.

Infini Resources is showcasing its Canadian uranium portfolio at the Ignite Investment Summit 2026, underscoring recent district-scale mineralisation and ambitious drilling campaigns planned across its Portland Creek and Athabasca margin projects.

TZ Limited reports steady sales growth and new Microsoft contracts in Q1 FY2026, reaffirming its $17–21 million revenue guidance amid improving market conditions.

Nanoveu Limited showcased its cutting-edge EMASS semiconductor technology at the Ignite Investment Summit in Hong Kong, highlighting a new ultra-low-power AI chip designed to revolutionize edge computing across multiple industries.

Battery Age Minerals (ASX – BM8) showcased its global portfolio of critical minerals projects at the Ignite Investment Summit in Hong Kong, highlighting maiden drilling at Austria’s Bleiberg germanium project, a newly granted drill permit for Argentina’s El Aguila gold-silver system, and ongoing lithium exploration in Canada’s Falcon Lake.